Urogen Pharma (NASDAQ:URGN) is scheduled to be announcing its earnings results before the market opens on Tuesday, November 14th. Analysts expect the company to announce earnings of $0.08 per share for the quarter.
Urogen Pharma (NASDAQ:URGN) opened at $41.04 on Friday. Urogen Pharma has a 52 week low of $13.01 and a 52 week high of $41.40.
A number of research analysts have recently issued reports on URGN shares. Jefferies Group LLC boosted their price objective on Urogen Pharma from $27.00 to $37.00 and gave the company a “buy” rating in a research note on Monday, October 9th. Zacks Investment Research downgraded Urogen Pharma from a “buy” rating to a “hold” rating in a research note on Friday, August 18th. Finally, Oppenheimer Holdings, Inc. set a $32.00 price objective on Urogen Pharma and gave the company a “buy” rating in a research note on Monday, August 14th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $28.50.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Markets Daily and is owned by of Markets Daily. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/11/12/urogen-pharma-urgn-set-to-announce-quarterly-earnings-on-tuesday.html.
Urogen Pharma Company Profile
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.